Evidence map›Paper›PMID 26084668›Full record

Trial reportCardiovascular diabetology2015

Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.

Hiroki Oe, Kazufumi Nakamura, Hajime Kihara, Kenei Shimada, Shota Fukuda, Tsutomu Takagi, Toru Miyoshi, Kumiko Hirata, Junichi Yoshikawa, Hiroshi Ito and 1 more

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 9 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 9 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Hiroki OeCenter of Ultrasonic Diagnostics, Okayama University Hospital, Okayama, Japan. hirokioe@gmail.com.
Kazufumi NakamuraDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan. ichibun@cc.okayama-u.ac.jp.
Hajime KiharaDepartment of Internal Medicine, Kihara Cardiovascular Clinic, Asahikawa, Japan. kiharah@potato.hokkai.net.
Kenei ShimadaDepartment of Internal Medicine and Cardiology, Osaka City University of Medicine, Osaka, Japan. shimadak@med.osaka-cu.ac.jp.
Shota FukudaDepartment of Medicine, Osaka Ekisaikai Hospital, Osaka, Japan. shota0022@gmail.com.
Tsutomu TakagiTakagi Cardiology Clinic, Kyoto, Japan. tcardiol@qb4.so-net.ne.jp.
Toru MiyoshiDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan. miyoshit@cc.okayama-u.ac.jp.
Kumiko HirataDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan. hirata8080@gmail.com.
Junichi YoshikawaNishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan. yoshikawaj@n-watanabe-hosp.jp.
Hiroshi ItoDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan. itomd@md.okayama-u.ac.jp.
FESC, for Effect of a DPP-4 inhibitor on left ventricular diastolic dysfunction in patients with type 2 diabetes and diabetic cardiomyopathy (3D) study investigators
Okayama University · JPOsaka City University · JPOkayama University Hospital · JPOsaka Ekisaikai Hospital · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeft ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes. Dipeptidyl peptidase-4 inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i, sitagliptin, and the alpha-glucosidase inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes.

methodsWe conducted a prospective, randomized, open-label, multicenter study of 100 diabetic patients with LV diastolic dysfunction. Patients received sitagliptin (50 mg/day) or voglibose (0.6 mg/day). The primary endpoints were changes in the e' velocity and E/e' ratio from baseline to 24 weeks later. The secondary efficacy measures included HbA1c, GLP-1, lipid profiles, oxidative stress markers and inflammatory markers.

resultsThe study was completed with 40 patients in the sitagliptin group and 40 patients in the voglibose group. There were no significant changes in the e' velocity and E/e' ratio from baseline to 24 weeks later in both groups. However, analysis of covariance demonstrated that pioglitazone use is an independent factor associated with changes in the e' and E/e' ratio. Among patients not using pioglitazone, e' increased and the E/e' ratio decreased in both the sitagliptin and voglibose groups. GLP-1 level increased from baseline to 24 weeks later only in the sitagliptin group (4.8 ± 4.7 vs. 7.3 ± 5.5 pmol/L, p < 0.05). The reductions in HbA1c and body weight were significantly greater in the sitagliptin group than in the voglibose group (-0.7 ± 0.6 % vs. -0.3 ± 0.4, p < 0.005; -1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg, p < 0.05, respectively). There were no changes in lipid profiles and inflammatory markers in both groups.

conclusionsOur trial showed that sitagliptin reduces HbA1c levels more greatly than voglibose does, but that neither was associated with improvement in the echocardiographic parameters of LV diastolic function in patients with diabetes.

trial registrationRegistered at http://www.umin.ac.jp under UMIN000003784.

Indexed as

AgedDiabetes Mellitus, Type 2DiastoleDipeptidyl-Peptidase IV InhibitorsEchocardiographyFemaleGlucagon-Like Peptide 1Glycated HemoglobinGlycoside Hydrolase InhibitorsHumansInositolMaleMiddle AgedSitagliptin PhosphateTreatment OutcomeVentricular Dysfunction, LeftDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Glycated HemoglobinGlycoside Hydrolase Inhibitorshemoglobin A1c protein, humanInositolSitagliptin Phosphatevoglibose

Identifiers

PMID26084668
PMCPMC4473835
OpenAlexW1582267185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.